Streetbeat News

Earnings

NBY

NovaBay Pharmaceuticals (AMEX:NBY) reported Q4 earnings with losses of $(0.21) per share, surpassing the $(0.30) estimate, and sales of $3.73M, exceeding the $3.40M estimate. This represents a significant improvement over the previous year's losses and a slight increase in sales.

Portfolio Pulse from dijoy@benzinga.com

March 26, 2024 | 9:18 pm

GPRO

GoPro announced a workforce reduction of about 4% to cut operating costs and improve operating leverage. The restructuring will cost an estimated $7.5 million, with $2.0 million in cash expenditures in Q1 2024 due to layoffs. The company also plans to reduce office space, leading to impairment charges of approximately $3.3 million in Q1 2024, with $2.2 million of these charges expected through January 2027. These restructuring charges will significantly impact GoPro's GAAP results for Q1 of the fiscal year ending December 31, 2024.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 9:16 pm

SOFI

Sofi Technologies has completed transactions as per exchange agreements, issuing 72.6M shares of common stock. These exchanges are anticipated to positively impact GAAP net income in Q1 of 2024.

Portfolio Pulse from Charles Gross

March 26, 2024 | 9:15 pm

GTBP

GT Biopharma (NASDAQ:GTBP) reported Q4 earnings, beating estimates with an EPS of $-2.14 against an expected $-2.7. However, revenue remained unchanged from the previous year. The company had previously seen an 8% share price increase following last quarter's earnings beat.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 9:15 pm

GTBP

GT Biopharma (NASDAQ:GTBP) reported a Q4 EPS loss of $(2.14), surpassing the analyst consensus estimate of $(2.70) by 20.74%. This represents a 60.37% improvement over the $(5.40) per share loss from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 9:14 pm

NOAH

Noah Holdings (NYSE:NOAH) reported a Q4 adjusted EPS of $0.47, up 51.61% from $0.31 YoY, but sales decreased 11.95% to $112.61M from $127.89M YoY.

Portfolio Pulse from mahesh@benzinga.com

March 26, 2024 | 9:10 pm

AP

ATLX

TMC

VALE

TMC The Metals Company, Ampco-Pittsburgh Corporation, Vale, and Atlas Lithium reported significant updates. TMC reported a reduced annual loss and highlighted progress in marine research. Ampco-Pittsburgh reported increased sales and operational losses due to asbestos charges but improved non-GAAP income. Vale is negotiating DOE funding for an iron ore briquette facility to reduce emissions. Atlas Lithium appointed a new COO to leverage Brazil's Lithium Valley reserves.

Portfolio Pulse from Austin DeNoce

March 26, 2024 | 9:09 pm

GTBP

GT Biopharma reported a Q4 net loss of $2.96M, an improvement from last year's $5.58M loss. With approximately $14M in cash as of December 31, 2023, the company expects to have enough funds to support operations into 2025.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 9:04 pm

V

In the latest quarter, 12 analysts provided mixed ratings for Visa (NYSE:V), with an average 12-month price target of $310.0, up 6.01% from the previous target. All analysts raised their price targets, reflecting optimism about Visa's performance and market position. Visa's financials show strong growth, profitability, and effective debt management, maintaining its status as the world's largest payment processor.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 9:01 pm

INTZ

Intrusion (NASDAQ:INTZ) reported Q4 earnings with losses of $(0.09) per share, surpassing the $(0.11) estimate, marking an 18.18% beat and a 64% improvement year-over-year. However, their quarterly sales of $1.37M fell short of the $1.64M estimate by 16.71%, representing a 5.40% decrease from the previous year.

Portfolio Pulse from dijoy@benzinga.com

March 26, 2024 | 9:00 pm